Background {#Sec1}
==========

The physician's assessment was for a long time the only factor that affected health care decisions, however in more recent years the necessity for a closer cooperation between physician and patient has been recognized. In this contest a key role is represented by the patient reported outcomes (PROs). Food and Drug Administration (FDA) defined PROs as any report coming directly from patients about their health condition and treatment \[[@CR1]\]. PROs can be used to measure overall concepts (e.g. state of general health), presence and intensity of specific symptoms, complex concepts, like the health related quality of life (HRQoL) \[[@CR2]--[@CR11]\]. In the field of HIV disease, symptoms play a central role in the life of HIV patients: they are the first reason the patient asks for care; they are strongly associated with HRQoL; they represent the patients experience of the drug adverse effects and disease effects \[[@CR12]--[@CR16]\]. Effective symptom management, aimed to decrease the burden of symptoms, could have a direct impact on improving the HRQoL and also an indirect impact on improving the adherence to antiretroviral therapy (ART) with expected positive impact on the efficacy of the treatment \[[@CR17]--[@CR20]\]. Moreover the clinical interpretation of the symptoms is easily understood by physicians with a likely immediate effect in clinical practice \[[@CR21]\]. It has also been shown that the symptoms reported directly by patients are more complete and more strongly associated with HRQoL than provider-reported symptoms. \[[@CR6]\]. It is therefore necessary that the presence and impact of symptoms are reported directly by the patient through the use of specific tools. An HIV specific symptom checklist might be the most suitable tool for routine clinical use \[[@CR21]\]. In the present paper we describe the development and the psychometric properties of the Istituto Superiore di Sanità-HIV symptoms scale (lSS-HIV symptoms scale).

Methods {#Sec2}
=======

The ISS-HIV symptom scale was developed by an Italian working team (coordinated by the Italian National Institute of Health, the ISS), including researchers, physicians and people living with HIV. The development process went through the following steps:

1. Review of existing HIV/AIDS literature {#Sec3}
-----------------------------------------

The first step in the development of the ISS-HIV symptoms scale was to review the symptoms measures available in literature. As a result of regular meeting the working team identified a list of symptoms to be included in the instrument.

2. Focus group {#Sec4}
--------------

Two focus groups were conducted on independent groups of approximately 10 HIV infected people. The patients were recruited both in clinical centers and patients' associations. The work done by focus groups resulted in a first draft of 38 HIV-related symptoms including.

3. Pre-test analysis {#Sec5}
--------------------

The first draft of the symptoms list was tested in a cross-sectional study on a group of 200 HIV + people, taking ART, recruited in two Italian clinical centers (Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona; Ospedale S. Maria della Misericordia, Perugia). Frequency analysis of symptoms and an exploratory principal components factor analysis were conducted. Based on these results, the preliminary item list has then been modified. Twenty-two of the 38 original symptoms were retained for the final version of the symptoms list.

4. HIV-ISS symptoms scale validation and final structure {#Sec6}
--------------------------------------------------------

A sample of 161 HIV + people on ART, enrolled in a cross-sectional study, from the two Italian clinical centers (Azienda Ospedaliera Universitaria Ospedali Riuniti, Ancona; Ospedale S. Maria della Misericordia, Perugia), was used to carry out the validation analysis. This study received ethics approval, and all patients provided written informed consent (*name of the Ethical Committee: Istituto Superiore di Sanità, Ethical Review Board*). The sample was defined on the basis of common practice in psychometric studies, according to which at least five cases for each item should be provided. In this study the case-to-item ration was approximately 7.3. The final version of HIV-ISS symptoms scale resulted in a self- administered list of 22 symptoms. A Likert five-point intensity scale was used to evaluate the impact of symptoms ([Appendix](#Sec15){ref-type="sec"}).

Statistical analysis {#Sec7}
====================

The statistical analyses reported in this study refer to validation analysis of HIV-ISS symptom scale including psychometric assumptions of validity and reliability \[[@CR22]\]. An instrument is said to be valid if it measures what it is supposed to measure. For this purpose we focused on the concurrent validity and construct validity. The construct validity of the HIV-ISS symptoms scale was assessed using principal components factor analysis with varimax rotation. As for concurrent validity, a step-wise multiple regressions were used to examine the relationship between the HIV-ISS symptoms scale and an external and independent measure of HRQoL. For this purpose the ISSQoL (Istituto Superiore di Sanità-Quality of Life), a validated specific questionnaire designed for people living with HIV, was used \[[@CR23], [@CR24]\]. The ISSQoL questionnaire includes 9 domains: physical functioning, role functioning, depression/anxiety, energy/vitality, health distress, cognitive functioning, social functioning, sexual life and satisfaction with quality of life. Reliability is defined as the degree to which repeated administration of a measurement instrument produces equivalent results under controlled conditions. In the present study the Cronbach's α coiffecient was used as an estimate of the test reliability. The range between 0.70 and 0.90 is considered as the minimum required value.

Results---validation analysis {#Sec8}
=============================

Description of the sample {#Sec9}
-------------------------

The characteristics of the sample used for the validation analysis are shown in Table [1](#Tab1){ref-type="table"}. The majority were men (75.8 %); 42.9 % were heterosexual. Median age was 49 years old. About more than half of the participants were asymptomatic (56.5 %) and they were HIV infected for a median of 13.5 years. Median HIV viral load was 1.6 log and median CD4 cell count was 611 cells/mm^3^.Table 1Characteristics of the population used for the validation analysisSex n (%) Female39 (24.2) Male122 (75.8)Age (years) Mean ± SD (n, range)49.0 ± 9.8 (161, 25--77) Median49.0Transmission route, n (%) Men having sex with men60 (37.3) Intravenous drug users26 (16.1) Heterosexual69 (42.9) Other6 (3.7)HIV status, n (%) Asymptomatic (CDC A)91 (56.5) Symptomatic (CDC B47 (29.2) AIDS (CDC C)23 (14.3)Time from HIV diagnosis (years) Mean ± SD (n, range)13.4 ± 9.2 (160, 0--30) Median13.5CD4 (cells/mm^3^) Mean ± SD (n, range)652 ± 312 (161, 24--1686) Median611HIV-RNA cp/ml (log~10~) Mean ± SD (n, range)1.76 ± 0.6 (161, 1--6) Median1.60

Construct validity {#Sec10}
------------------

The 22 symptoms of HIV-ISS symptoms scale were clustered in five factors that explained 64.96 % of variance (Table [2](#Tab2){ref-type="table"}): pain/general discomfort (7 items);depression/anxiety (4 items); emotional reaction/psychological distress (5 items); gastrointestinal discomfort (4 items);sexual discomfort (2 items);Table 2Factor structure and reliability estimatesISS-HIV symptom scales ItemsLoadings% VarianceChronbach's α*Factor 1: Pain/general discomfort (7 items)*16.250.86Pain in the head or feet0.769Aching muscles0.691Abnormal accumulation of fat0.681Abdominal bloating0.563Sweating0.513Impaired vision0.498Headache0.475*Factor 2: Depression, anxiety (4 items*)16.030.87Feeling sad0.817Worrying0.758Feeling anxious and nervous0.718Sleep problems0.574*Factor 3: Emotional reaction/psychological distress (5 items)*13.080.83Memory problems0.739Coughing0.692Shortness of breath0.608Difficulty in concentrating0.591Tiredness0.488*Factor 4: Gastrointestinal discomfort (4 items)*10.020.70Weight loss0.715Lack of appetite0.702Diarrhoea0.656Heartburn0.508*Factor 5: Sexual discomfort (2 items)*9.580.91Decrease of sexual interest0.790Problem with sexual activity0.758

Reliability {#Sec11}
-----------

The Chronbach's α scores were for all factors within the minimum accepted standard of 0.70 (Table [2](#Tab2){ref-type="table"}).

Concurrent validity {#Sec12}
-------------------

Step-wise multiple regressions were used for each ISSQoL domain as dependent variable and the five factors of the HIV-ISS symptoms scale as predictor variables. The HIV-ISS symptoms scale concurrent validity was tested based on the following hypothesized significant relationships: (1) pain/general discomfort with physical functioning, social functioning, depression/anxiety, energy/vitality, sexual life and satisfaction with quality of life; (2) depression/anxiety with all ISSQoL domains; (3) emotional reaction/psychological distress with social functioning, depression/anxiety, energy/vitality, cognitive functioning, satisfaction with quality of life; (4) gastrointestinal discomfort with social functioning, depression/anxiety, energy/vitality; (5) sexual discomfort with social functioning, depression/anxiety, sexual life, satisfaction with quality of life. All hypothesized relationships were confirmed (Table [3](#Tab3){ref-type="table"}).Table 3Regression analysis between ISS-HIV factors scores and ISS-Qol questionnaire**ISSQoL domains (dependent variables)ISS-HIV factors score (predictors)**Standardized\
coefficients (Beta)pPhysical functioningFactor 1---Pain/general discomfort0.250.001Factor 2---Depression, anxiety0.230.001Factor 3---Emotional reaction/psychological distress0.160.030Factor 4---Gastrointestinal discomfort0.130.068Factor 5---Sexual discomfort0.290.000Role functioningFactor 1---Pain/general discomfort−0.020.827Factor 2---Depression, anxiety0.230.005Factor 3---Emotional reaction/psychological distress0.170.033Factor 4---Gastrointestinal discomfort0.090.262Factor 5---Sexual discomfort0.170.039Social functioningFactor 1---Pain/general discomfort0.220.001Factor 2---Depression, anxiety0.420.000Factor 3---Emotional reaction/psychological distress0.190.004Factor 4---Gastrointestinal discomfort0.190.005Factor 5---Sexual discomfort0.220.001Depression/anxietyFactor 1---Pain/general discomfort0.330.000Factor 2---Depression, anxiety0.650.000Factor 3---Emotional reaction/psychological distress0.260.000Factor 4---Gastrointestinal discomfort0.230.000Factor 5---Sexual discomfort0.270.000Energy/vitalityFactor 1---Pain/general discomfort0.190.002Factor 2---Depression, anxiety0.400.000Factor 3---Emotional reaction/psychological distress0.410.000Factor 4---Gastrointestinal discomfort0.160.009Factor 5---Sexual discomfort0.130.032Health distressFactor 1---Pain/general discomfort0.220.000Factor 2---Depression, anxiety0.580.000Factor 3---Emotional reaction/psychological distress0.060.353Factor 4---Gastrointestinal discomfort0.170.006Factor 5---Sexual discomfort0.230.000Cognitive functioningFactor 1---Pain/general discomfort0.190.001Factor 2---Depression, anxiety0.460.000Factor 3---Emotional reaction/psychological distress0.390.000Factor 4---Gastrointestinal discomfort0.170.004Factor 5---Sexual discomfort0.190.001Sexual lifeFactor 1---Pain/general discomfort0.220.002Factor 2---Depression, anxiety0.350.000Factor 3---Emotional reaction/psychological distress0.030.623Factor 4---Gastrointestinal discomfort−0.050.459Factor 5---Sexual discomfort0.390.000Satisfaction with quality of lifeFactor 1---Pain/general discomfort0.290.000Factor 2---Depression, anxiety0.460.000Factor 3---Emotional reaction/psychological distress0.140.033Factor 4---Gastrointestinal discomfort0.070.285Factor 5---Sexual discomfort0.190.003

Discussion {#Sec13}
==========

The results of this study provide a preliminary evidence of the reliability and validity of the 22-item ISS-HIV symptoms scale. Factor analysis showed a good evidence for construct validity and internal consistency reliability. A good concurrent validity was also demonstrated. The regression analysis supported the evidence for the concurrent validity of the ISS-HIV symptoms scale factors with the ISSQoL domains. In the new era where HIV infection has been transformed into a chronic diseases and patients are experiencing a complex range of symptoms due to HIV infection, side effects of antiretroviral therapy (ART) and also associated comorbidities, the ISS-HIV symptoms scale may represent an updated and useful tool for a comprehensive symptom assessment and control in clinical practice.

Routine use of the symptoms assessment in the clinical practice could improve the communication between patient and clinician and this would make it possible to take targeted actions to manage the presence of particular symptom clusters \[[@CR3], [@CR25]\]. The use of patient-reported symptoms in clinical practice could not only improve clinician-patient communication, but also would allow to understand the changes in patient well-being over time, leading clinicians to therapeutic choices targeted to individual patients with a positive effect on individual patient management and outcomes \[[@CR26]--[@CR29]\]. The ISS-HIV symptoms scale has the advantage of being easy to fill out by patients and potentially attractive to physicians mainly because it is easy to understand and requires short time to interpret the results. The ISS-HIV Symptom Scale can be suitable for routine use in clinical practice, both as a single screening tool and in conjunction with other specific instruments. The simultaneous use of multiple instruments can be strategically significant in the presence of high-impact specific symptoms. The ISS-HIV Symptom Scale is able to detect the most frequent symptoms, as well as symptoms that may highly affect the patient's quality of life. More specific instruments, such as those for pain or anxiety detection, could then be used to achieve more accurate information.

Considering also the recent agenda by the Patient-Centered Outcomes Research Institute (PCORI) that calls for a greater involvement of patients in assessing health care options, the systematic collection of PROs should be widely recommended \[[@CR30]\]. As some experts in outcomes research have already experienced, a website, where PRO measures are collected in electronic health records (EHR) and linked to electronic medical record (EMR), can be a useful innovative tool to improve and stimulate the use of patient reported data in clinical practice \[[@CR31], [@CR32]\]. Clinicians would have the advantage to use PROs measure as a part of patients information along with laboratory and clinical data. The HIV-ISS symptoms scale, a short and comphrensive list of symptoms and easy to administer both by patients and clinicians, may be suitable for this purpose. The present study has several limitations. First, the construct validity of HIV-ISS Symptoms scale has not been supported by a confirmatory factor analysis. Moreover, a responsiveness assessment of the instrument would also be necessary. Generalization of results is limited to the Italian context where the validation analysis has been performed. Additional studies should address the reproducibility of index symptoms.

Conclusions {#Sec14}
===========

The results of this study show that ISS-HIV symptoms scale is a self-administered tool, with characteristics of validity and reliability, able to provide useful measures patient-centered. A more complete detection of symptoms and their appropriate management may positively impact on the HRQoL of the patients and, indirectly, increase adherence to ART with expected positive impact on the efficacy of the treatment.

Appendix {#Sec15}
========

ISS-HIV symptoms scale. See Table [4](#Tab4){ref-type="table"}.Table 4Have you suffered from any of the following symptoms over the past 4 weeks? A very great dealNot at allA littleModeratelyA lotA very great deal1.Tiredness□□□□□2.Lack of appetite□□□□□3.Weight loss□□□□□4.Diarrhoea□□□□□5.Heartburn□□□□□6.Mental confusion□□□□□7.Memory problems□□□□□8.Sleep problems□□□□□9.Impaired vision□□□□□10.Coughing□□□□□11.Shortness of breath□□□□□12.Sweating□□□□□13.Problems with sexual activity□□□□□14.Decrease of sexual interest□□□□□15.Abdominal bloating□□□□□16.Abnormal accumulation of fat□□□□□17.Headache□□□□□18.Aching muscles□□□□□19.Pain in the hands or feet□□□□□20.Worrying□□□□□21.Feeling sad□□□□□22.Feeling anxious and nervous□□□□□

PROs

:   patient reported outcomes

HRQoL

:   health related quality of life

ART

:   antiretroviral therapy

lSS-HIV symptoms scale

:   Istituto Superiore di Sanità-HIV symptoms scale

ISSQoL

:   Istituto Superiore di Sanità-Quality of Life

PCORI

:   Patient-Centered Outcomes Research Institute

EHR

:   electronic health records

EMR

:   electronic medical records
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